These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37181609)

  • 1. Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes.
    Moradian S; Soheilian M; Asadi M; Baghi A; Safi H; Abtahi SH
    J Ophthalmic Vis Res; 2023; 18(2):164-169. PubMed ID: 37181609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Doses of Intravitreal Ziv-Aflibercept versus Bevacizumab in Treatment of Diabetic Macular Edema: A Three-Armed, Double-Blind Randomized Trial.
    Baghi A; Jabbarpoor Bonyadi MH; Ramezani A; Azarmina M; Moradian S; Dehghan MH; Nourinia R; Peyman GA; Yaseri M; Soheilian M
    Ophthalmol Retina; 2017; 1(2):103-110. PubMed ID: 31047266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
    Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
    Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
    Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
    Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
    Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.
    Nourinia R; Ahmadieh H; Nekoei E; Malekifar P; Tofighi Z
    Retina; 2018 May; 38(5):970-975. PubMed ID: 28426622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness.
    Sariyeva Ismayılov A; Esen E; Sızmaz S; Demircan AN
    Clin Exp Optom; 2019 Nov; 102(6):617-620. PubMed ID: 30793798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema.
    Dweikat A; Jarrar A; Akkawi M; Shehadeh M; Aghbar A; Qaddumi J; Akkawi M
    Clin Ophthalmol; 2021; 15():4175-4180. PubMed ID: 34703204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
    Nawar AE; Wasfy T; Shafik HM
    BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
    Savur F; Kaldırım H; Atalay K; Korkmaz Ş
    Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
    Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
    Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion.
    Paulose R; Chhablani J; Dedhia CJ; Stewart MW; Mansour AM
    Clin Ophthalmol; 2016; 10():1853-1858. PubMed ID: 27703326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population.
    Braimah IZ; Amoaku WM
    Eye (Lond); 2022 May; 36(Suppl 1):40-44. PubMed ID: 35590054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
    Braimah IZ; Agyabeng K; Amoaku WM
    Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical coherence tomography classifications of diabetic macular edema and response to aflibercept: One-year follow-up outcomes in a Chinese population.
    Gu Z; Xi T; Zhang C; Yang G
    Medicine (Baltimore); 2023 Jan; 102(4):e32815. PubMed ID: 36705371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
    Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J
    Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subfoveal choroidal thickness following pars plana vitrectomy in tractional diabetic macular edema.
    Dourandeesh M; Moeini M; Shaye ZA; Shoeibi N; Hosseini SM; Banaee T
    Eur J Ophthalmol; 2023 May; 33(3):1405-1411. PubMed ID: 36476066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.